US OptionsDetailed Quotes
MCRB250117P500
- 0.05
- 0.000.00%
15min DelayClose Dec 27 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume1.08K Open Interest0.50Strike Price0.00Turnover300.08%IV49.21%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.1192Delta0.3258Gamma17.74Leverage Ratio-0.0032Theta-0.0001Rho-2.11Eff Leverage0.0004Vega
Seres Therapeutics Stock Discussion
Sign in to post a comment
$Seres Therapeutics (MCRB.US)$ may this fly later. (:
1
$Seres Therapeutics (MCRB.US)$ Reuters· 3 mins ago
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
$Seres Therapeutics (MCRB.US)$
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Ser...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Ser...
No comment yet
flabbyduck OP : let's wait for people to jump from ldtc to this. come onnn